Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION 4: zenagamtide versus lower-dose semaglutide in type 2 diabetes
2026-525474-20-00Phase 3Authorised
- Sponsor
- Novo Nordisk
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Zenagamtide once weekly with Semaglutide once weekly (2 arms). Primary endpoint: Change in glycated haemoglobin A1c (HbA1c). Planned start Oct 2026; status: authorised.
02
Drugs
amycretinsemaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2026-525474-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525474-20-00.